Syed Abrar, MD
Internal Medicine · Houston, TXNPI 1912178039
Payments from drug & device makers
Across 217 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$735
- Otsuka America Pharmaceutical, Inc.$581
- Takeda Pharmaceuticals U.S.A., Inc.$497
- Corium, LLC$435
- Neos Therapeutics, LP$356
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$294
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,156100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 35 | $735 |
| Otsuka America Pharmaceutical, Inc. | 33 | $581 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $497 |
| Corium, LLC | 18 | $435 |
| Neos Therapeutics, LP | 26 | $356 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $294 |
| Neurocrine Biosciences, Inc. | 11 | $271 |
| Teva Pharmaceuticals USA, Inc. | 9 | $192 |
| Alkermes, Inc. | 8 | $179 |
| AbbVie(2 entities) | 8 | $156 |
| Bausch Health US, LLC | 4 | $62 |
| Noven Therapeutics, LLC | 3 | $54 |
| Biogen | 2 | $51 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Almatica Pharma LLC | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 3 | $48 |
| Shire North American Group Inc | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Johnson & Johnson | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Aytu Biopharma, Inc. | 2 | $15 |
How this compares
$4,156 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 16 | $16,087 |
| JanuviaSitagliptin Phosphate | 12 | $8,286 |
| JardianceEmpagliflozin | 15 | $6,680 |
| Cyclosporine | 14 | $3,444 |
| Levothyroxine Sodium | 156 | $1,689 |
| PaxlovidNirmatrelvir/Ritonavir | 14 | $1,429 |
| Nifedipine ErNifedipine | 39 | $1,392 |
| Atorvastatin Calcium | 178 | $1,329 |
| Pantoprazole Sodium | 117 | $1,289 |
| Ezetimibe | 16 | $1,264 |
| Metoprolol Succinate | 66 | $764 |
| Rosuvastatin Calcium | 63 | $753 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $746 |
| Omeprazole | 40 | $745 |
| Fluticasone Propionate | 60 | $726 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.